Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with View All
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q1 2024 | ANHYDROUS DEXTROSE | NASAL | SPRAY, METERED | 200mg | Correction | ||
| Q2 2024 | ANHYDROUS DEXTROSE | NASAL | SPRAY, METERED | 25mg | Correction | ||
| Q1 2024 | BORIC ACID | OPHTHALMIC | SUSPENSION | 0.30 %w/v | Correction | ||
| Q2 2024 | BORIC ACID | OPHTHALMIC | SUSPENSION | 0.25 %w/v | Correction | ||
| Q1 2024 | CELLULOSE MICROCRYSTALLINE/CARBOXYMETHYLCELLULOSE SODIUM | NASAL | SPRAY, METERED | 60mg | Correction | ||
| Q2 2024 | CELLULOSE MICROCRYSTALLINE/CARBOXYMETHYLCELLULOSE SODIUM | NASAL | SPRAY, METERED | 8mg | Correction | ||
| Q1 2024 | CITRIC ACID MONOHYDRATE | ORAL | SUSPENSION | 330mg | Correction | ||
| Q2 2024 | CITRIC ACID MONOHYDRATE | ORAL | SUSPENSION | 269mg | Correction | ||
| Q1 2024 | DIETHYLENE GLYCOL MONO AND DIPALMITOSTEARATE | VAGINAL | CREAM | 16500mg | Correction | ||
| Q2 2024 | DIETHYLENE GLYCOL MONO- AND DIPALMITOSTEARATE | VAGINAL | CREAM | 16500mg | Correction | ||
| Q1 2024 | DURO-TAK 87-2070 | TRANSDERMAL | FILM, EXTENDED RELEASE | NA | Correction | ||
| Q2 2024 | ACRYLIC ACID-2-ETHYLHEXYL ACRYLATE-2-HYDROXYETHYL ACRYLATE-VINYL ACETATE COPOLYMER (FOR DURO-TAK 87-2070) | TRANSDERMAL | FILM, EXTENDED RELEASE | NA | Correction | ||
| Q1 2024 | DURO-TAK 87-2070 | TRANSDERMAL | SYSTEM | NA | Correction | ||
| Q2 2024 | ACRYLIC ACID-2-ETHYLHEXYL ACRYLATE-2-HYDROXYETHYL ACRYLATE-VINYL ACETATE COPOLYMER (FOR DURO-TAK 87-2070) | TRANSDERMAL | SYSTEM | NA | Correction | ||
| Q1 2024 | DURO-TAK 87-2194 | TRANSDERMAL | FILM, EXTENDED RELEASE | 208.28 mg | Correction | ||
| Q2 2024 | 2-ETHYLHEXYL ACRYLATE-VINYL ACETATE-ALUMINUM ACRYLATE COPOLYMER (FOR DURO-TAK 87-2194) | TRANSDERMAL | FILM, EXTENDED RELEASE | NA | Correction | ||
| Q1 2024 | DURO-TAK 87-2287 | TRANSDERMAL | FILM | 537.70 mg | Correction | ||
| Q2 2024 | 2-ETHYLHEXYL ACRYLATE-GLYCIDYL METHACRYLATE-2-HYDROXYETHYL ACRYLATE-VINYL ACETATE COPOLYMER (FOR DURO-TAK 387-2287) | TRANSDERMAL | FILM | NA | Correction | ||
| Q1 2024 | DURO-TAK 87-2287 | TRANSDERMAL | FILM, EXTENDED RELEASE | 121.10 mg | Correction | ||
| Q2 2024 | 2-ETHYLHEXYL ACRYLATE-GLYCIDYL METHACRYLATE-2-HYDROXYETHYL ACRYLATE-VINYL ACETATE COPOLYMER (FOR DURO-TAK 387-2287) | TRANSDERMAL | FILM, EXTENDED RELEASE | NA | Correction | ||
| Q1 2024 | DURO-TAK 87-2287 | TRANSDERMAL | SYSTEM | 305.89 mg | Correction | ||
| Q2 2024 | 2-ETHYLHEXYL ACRYLATE-GLYCIDYL METHACRYLATE-2-HYDROXYETHYL ACRYLATE-VINYL ACETATE COPOLYMER (FOR DURO-TAK 387-2287) | TRANSDERMAL | SYSTEM | NA | Correction | ||
| Q1 2024 | FD&C YELLOW NO. 6 ALUMINUM LAKE | ORAL | TABLET, FILM COATED | 2mg | Correction | ||
| Q2 2024 | FD&C YELLOW NO. 6 ALUMINUM LAKE | ORAL | TABLET, FILM COATED | 0.39 mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | CAPSULE | 765.00 mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | CAPSULE | 13770mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | CAPSULE, DELAYED RELEASE | 24mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | CAPSULE, DELAYED RELEASE | 24mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | CAPSULE, GELATIN COATED | 62.20 mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | CAPSULE, GELATIN COATED | 62.20 mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | CAPSULE, LIQUID FILLED | 139.00 mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | CAPSULE, LIQUID FILLED | 139mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | SOLUTION | 30.00 mg/ 1.00 ml | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | SOLUTION | 300mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | TABLET | 1.30 mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | TABLET | 1.30 mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DIPALMITOSTEARATE | ORAL | CAPSULE | 16mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DIPALMITOSTEARATE | ORAL | CAPSULE | 16mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DIPALMITOSTEARATE | ORAL | CAPSULE, DELAYED RELEASE | 25mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DIPALMITOSTEARATE | ORAL | CAPSULE, DELAYED RELEASE | 25mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DIPALMITOSTEARATE | ORAL | TABLET, DELAYED RELEASE | 3mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DIPALMITOSTEARATE | ORAL | TABLET, DELAYED RELEASE | 3mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DIPALMITOSTEARATE | ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 28mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DIPALMITOSTEARATE | ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 28mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DIPALMITOSTEARATE | TOPICAL | CREAM | 312mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DIPALMITOSTEARATE | TOPICAL | CREAM | 312mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DIPALMITOSTEARATE | VAGINAL | CREAM | 160mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DIPALMITOSTEARATE | VAGINAL | CREAM | 160mg | Correction | ||
| Q1 2024 | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | ORAL | CAPSULE, EXTENDED RELEASE | 214mg | Correction | ||
| Q2 2024 | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | ORAL | CAPSULE, EXTENDED RELEASE | 204mg | Correction | ||
| Q1 2024 | HYPROMELLOSE 2910 (4000 MPA.S) | OPHTHALMIC | GEL | 197mg | Correction | ||
| Q2 2024 | HYPROMELLOSE 2910 (4000 MPA.S) | OPHTHALMIC | GEL | 1mg | Correction | ||
| Q1 2024 | LECITHIN, SOYBEAN | ORAL | CAPSULE | 20.00 mg | Correction | ||
| Q2 2024 | SOYBEAN LECITHIN | ORAL | CAPSULE | 20.00 mg | Correction | ||
| Q1 2024 | LECITHIN, SOYBEAN | ORAL | POWDER, FOR SUSPENSION | 39mg | Correction | ||
| Q2 2024 | SOYBEAN LECITHIN | ORAL | POWDER, FOR SUSPENSION | 39mg | Correction | ||
| Q1 2024 | LECITHIN, SOYBEAN | ORAL | TABLET | 8mg | Correction | ||
| Q2 2024 | SOYBEAN LECITHIN | ORAL | TABLET | 8mg | Correction | ||
| Q1 2024 | LECITHIN, SOYBEAN | ORAL | TABLET, EXTENDED RELEASE | 20mg | Correction | ||
| Q2 2024 | SOYBEAN LECITHIN | ORAL | TABLET, EXTENDED RELEASE | 20mg | Correction | ||
| Q1 2024 | LECITHIN, SOYBEAN | ORAL | TABLET, FILM COATED | 0.33 mg | Correction | ||
| Q2 2024 | SOYBEAN LECITHIN | ORAL | TABLET, FILM COATED | 0.33 mg | Correction | ||
| Q1 2024 | LECITHIN, SOYBEAN | RESPIRATORY (INHALATION) | AEROSOL, METERED | 0.10 %w/w | Correction | ||
| Q2 2024 | SOYBEAN LECITHIN | RESPIRATORY (INHALATION) | AEROSOL, METERED | 0.10 %w/w | Correction | ||
| Q1 2024 | LECITHIN, SOYBEAN | VAGINAL | CREAM | 1.00 %w/w | Correction | ||
| Q2 2024 | SOYBEAN LECITHIN | VAGINAL | CREAM | 1.00 %w/w | Correction | ||
| Q1 2024 | PHENYLETHYL ALCOHOL | NASAL | SPRAY, METERED | 10mg | Correction | ||
| Q2 2024 | PHENYLETHYL ALCOHOL | NASAL | SPRAY, METERED | 2mg | Correction | ||
| Q1 2024 | POLYVINYL ALCOHOL | ORAL | CAPSULE, EXTENDED RELEASE | 6mg | Correction | ||
| Q2 2024 | POLYVINYL ALCOHOL | ORAL | CAPSULE, EXTENDED RELEASE | 3mg | Correction | ||
| Q1 2024 | POVIDONE | ORAL | CAPSULE, EXTENDED RELEASE | 120mg | Correction | ||
| Q2 2024 | POVIDONE | ORAL | CAPSULE, EXTENDED RELEASE | 56mg | Correction | ||
| Q1 2024 | PROSOLV | ORAL | TABLET, EXTENDED RELEASE | 791mg | Correction | ||
| Q2 2024 | PROSOLV ODT | ORAL | TABLET, EXTENDED RELEASE | 791mg | Correction | ||
| Q1 2024 | PROSOLV | ORAL | TABLET, ORALLY DISINTEGRATING | 240.07 mg | Correction | ||
| Q2 2024 | PROSOLV ODT | ORAL | TABLET, ORALLY DISINTEGRATING | 361mg | Correction | ||
| Q2 2024 | AMMONIA SOLUTION | ORAL | CAPSULE, LIQUID FILLED | NA | Deletion | ||
| Q2 2024 | ANHYDROUS CITRIC ACID | ORAL | TABLET, FILM COATED | 4.50 mg | 27mg | Deletion | |
| Q2 2024 | ASPARTAME | ORAL | SUSPENSION | 50.00 mg/ 5.00 ml | 420mg | Deletion | |
| Q2 2024 | CARRAGEENAN | TRANSDERMAL | FILM, EXTENDED RELEASE | 33.00 mg | Deletion | ||
| Q2 2024 | CETEARYL ETHYLHEXANOATE | TOPICAL | CREAM | 3.00 %w/w | Deletion | ||
| Q2 2024 | CITRIC ACID MONOHYDRATE | INTRAVENOUS | POWDER, FOR SOLUTION | 0.09 %w/v | Deletion | ||
| Q2 2024 | D&C RED NO. 21--ALUMINUM LAKE | ORAL | CAPSULE | NA | Deletion | ||
| Q2 2024 | D&C RED NO. 21--ALUMINUM LAKE | ORAL | TABLET, CHEWABLE | NA | Deletion | ||
| Q2 2024 | DEXTROSE | INTRAVENOUS | POWDER, FOR SOLUTION | 5.02 %w/v | Deletion | ||
| Q2 2024 | ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER (2:1; 750000 MW) | ORAL | CAPSULE | 116.89 mg | 135mg | Deletion | |
| Q2 2024 | FERROSOFERRIC OXIDE | ORAL | CAPSULE, LIQUID FILLED | NA | Deletion | ||
| Q2 2024 | HYDROCHLORIC ACID | INTRAVENOUS | POWDER, FOR SOLUTION | ADJ PH | Deletion | ||
| Q2 2024 | HYPROMELLOSE | NASAL | SPRAY | 1.00 mg/ 1.00 ml | 1mg | Deletion | |
| Q2 2024 | HYPROMELLOSE | ORAL | SOLUTION | 3.70 mg/ 1.00 ml | Deletion | ||
| Q2 2024 | METHYLCELLULOSE | OPHTHALMIC | SOLUTION/ DROPS | 0.50 %w/v | Deletion | ||
| Q2 2024 | OPASPRAY K-1-2656 BEIGE | ORAL | TABLET, FILM COATED | 3.36 mg | 7mg | Deletion | |
| Q2 2024 | POLYETHYLENE GLYCOL 200 | ORAL | TABLET, EXTENDED RELEASE | NA | Deletion | ||
| Q2 2024 | POLYETHYLENE GLYCOL 4500 | ORAL | TABLET, COATED | NA | Deletion | ||
| Q2 2024 | POLYOXYL GLYCERYL STEARATE | TOPICAL | CREAM | 5.00 %w/w | Deletion | ||
| Q2 2024 | POVIDONE | TRANSDERMAL | SOLUTION | 2.00 %w/v | Deletion | ||
| Q2 2024 | SHELLAC | ORAL | CAPSULE, LIQUID FILLED | NA | Deletion | ||
| Q2 2024 | SODIUM BISULFITE | OPHTHALMIC | SUSPENSION | 0.06 %w/w | Deletion | ||
| Q2 2024 | SODIUM HYDROXIDE | INTRAVENOUS | POWDER, FOR SOLUTION | ADJ PH | Deletion | ||
| Q1 2024 | ANHYDROUS CITRIC ACID | NASAL | SPRAY | 26.03 mg/ 1.00 ml | MDE Replacement | ||
| Q2 2024 | ANHYDROUS CITRIC ACID | NASAL | SPRAY | 5mg | MDE Replacement | ||
| Q1 2024 | ANHYDROUS TRISODIUM CITRATE | ORAL | GRANULE, FOR SUSPENSION | 400.00 mg/ 5.00 ml | MDE Replacement | ||
| Q2 2024 | ANHYDROUS TRISODIUM CITRATE | ORAL | GRANULE, FOR SUSPENSION | 4000mg | MDE Replacement | ||
| Q1 2024 | ASCORBIC ACID | INTRAMUSCULAR | INJECTION | 0.20 %w/v | MDE Replacement | ||
| Q2 2024 | ASCORBIC ACID | INTRAMUSCULAR | INJECTION | 192mg | MDE Replacement | ||
| Q1 2024 | CARBOXYMETHYLCELLULOSE SODIUM | TOPICAL | SOLUTION | 0.50 %w/w | MDE Replacement | ||
| Q2 2024 | CARBOXYMETHYLCELLULOSE SODIUM | TOPICAL | SOLUTION | 3000mg | MDE Replacement | ||
| Q1 2024 | CITRIC ACID MONOHYDRATE | SUBCUTANEOUS | INJECTION | 1.26 %w/v | MDE Replacement | ||
| Q2 2024 | CITRIC ACID MONOHYDRATE | SUBCUTANEOUS | INJECTION | 28mg | MDE Replacement | ||
| Q1 2024 | D&C RED NO. 30 ALUMINUM LAKE | ORAL | CAPSULE, DELAYED RELEASE | 0.30 mg | MDE Replacement | ||
| Q2 2024 | D&C RED NO. 30 ALUMINUM LAKE | ORAL | CAPSULE, DELAYED RELEASE | 5mg | MDE Replacement | ||
| Q1 2024 | D&C RED NO. 30 ALUMINUM LAKE | ORAL | TABLET, EXTENDED RELEASE | 0.10 mg | MDE Replacement | ||
| Q2 2024 | D&C RED NO. 30 ALUMINUM LAKE | ORAL | TABLET, EXTENDED RELEASE | 1mg | MDE Replacement | ||
| Q1 2024 | EDETATE DISODIUM | OPHTHALMIC | SUSPENSION/ DROPS | 0.10 %w/v | MDE Replacement | ||
| Q2 2024 | EDETATE DISODIUM | OPHTHALMIC | SUSPENSION/ DROPS | 1mg | MDE Replacement | ||
| Q1 2024 | ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A | ORAL | TABLET | 12.75 mg | MDE Replacement | ||
| Q2 2024 | ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A | ORAL | TABLET | 23mg | MDE Replacement | ||
| Q1 2024 | FD&C YELLOW NO. 6 | ORAL | CAPSULE, LIQUID FILLED | 0.18 mg | MDE Replacement | ||
| Q2 2024 | FD&C YELLOW NO. 6 | ORAL | CAPSULE, LIQUID FILLED | 1mg | MDE Replacement | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | CAPSULE | 765.00 mg | MDE Replacement | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | CAPSULE | 13770mg | MDE Replacement | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | CAPSULE, LIQUID FILLED | 139.00 mg | MDE Replacement | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | CAPSULE, LIQUID FILLED | 139mg | MDE Replacement | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | SOLUTION | 30.00 mg/ 1.00 ml | MDE Replacement | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | SOLUTION | 300mg | MDE Replacement | ||
| Q1 2024 | HYDROXYETHYL CELLULOSE (4000 MPA.S AT 1%) | OPHTHALMIC | SOLUTION/ DROPS | 0.48 %w/v | MDE Replacement | ||
| Q2 2024 | HYDROXYETHYL CELLULOSE (4000 MPA.S AT 1%) | OPHTHALMIC | SOLUTION/ DROPS | 1mg | MDE Replacement | ||
| Q1 2024 | HYPROMELLOSE 2208 (15000 MPA.S) | ORAL | TABLET | 323.28 mg | MDE Replacement | ||
| Q2 2024 | HYPROMELLOSE 2208 (15000 MPA.S) | ORAL | TABLET | 375mg | MDE Replacement | ||
| Q1 2024 | LACTOSE MONOHYDRATE | ORAL | CAPSULE, EXTENDED RELEASE | 536.40 mg | MDE Replacement | ||
| Q2 2024 | LACTOSE MONOHYDRATE | ORAL | CAPSULE, EXTENDED RELEASE | 5364mg | MDE Replacement | ||
| Q1 2024 | LANOLIN | RECTAL | OINTMENT | 14.00 %w/w | MDE Replacement | ||
| Q2 2024 | LANOLIN | RECTAL | OINTMENT | 105mg | MDE Replacement | ||
| Q1 2024 | LAURYL LACTATE | TRANSDERMAL | FILM, EXTENDED RELEASE | 12.00 mg | MDE Replacement | ||
| Q2 2024 | LAURYL LACTATE | TRANSDERMAL | FILM, EXTENDED RELEASE | 12mg | MDE Replacement | ||
| Q1 2024 | METHYLCELLULOSE | OPHTHALMIC | SUSPENSION | 0.05 %w/w | MDE Replacement | ||
| Q2 2024 | METHYLCELLULOSE | OPHTHALMIC | SUSPENSION | 1mg | MDE Replacement | ||
| Q1 2024 | METHYLPARABEN | ORAL | GRANULE, FOR SUSPENSION | 8.00 mg/ 5.00 ml | MDE Replacement | ||
| Q2 2024 | METHYLPARABEN | ORAL | GRANULE, FOR SUSPENSION | 80mg | MDE Replacement | ||
| Q1 2024 | OPADRY II Y-30-18037 WHITE | ORAL | TABLET | 38.00 mg | MDE Replacement | ||
| Q2 2024 | OPADRY II Y-30-18037 WHITE | ORAL | TABLET | 62mg | MDE Replacement | ||
| Q1 2024 | OPADRY II Y-30-18037 WHITE | ORAL | TABLET, EXTENDED RELEASE | 33.00 mg | MDE Replacement | ||
| Q2 2024 | OPADRY II Y-30-18037 WHITE | ORAL | TABLET, EXTENDED RELEASE | 88mg | MDE Replacement | ||
| Q1 2024 | POLOXAMER 407 | OPHTHALMIC | GEL | 0.20 %w/w | MDE Replacement | ||
| Q2 2024 | POLOXAMER 407 | OPHTHALMIC | GEL | 1mg | MDE Replacement | ||
| Q1 2024 | PROPYLPARABEN | TOPICAL | SOLUTION | 0.10 %w/v | MDE Replacement | ||
| Q2 2024 | PROPYLPARABEN | TOPICAL | SOLUTION | 24mg | MDE Replacement | ||
| Q1 2024 | PROSOLV | ORAL | TABLET, ORALLY DISINTEGRATING | 240.07 mg | MDE Replacement | ||
| Q2 2024 | PROSOLV ODT | ORAL | TABLET, ORALLY DISINTEGRATING | 361mg | MDE Replacement | ||
| Q1 2024 | PROSOLV 50 | ORAL | CAPSULE | 33.86 mg | MDE Replacement | ||
| Q2 2024 | PROSOLV 50 | ORAL | CAPSULE | 33mg | MDE Replacement | ||
| Q1 2024 | PROSOLV 90 | ORAL | CAPSULE | 50.78 mg | MDE Replacement | ||
| Q2 2024 | PROSOLV 90 | ORAL | CAPSULE | 50mg | MDE Replacement | ||
| Q1 2024 | PROSOLV 90 | SUBLINGUAL | TABLET | 18.70 mg | MDE Replacement | ||
| Q2 2024 | PROSOLV 90 | SUBLINGUAL | TABLET | 19mg | MDE Replacement | ||
| Q1 2024 | SACCHARIN | ORAL | GRANULE, FOR SOLUTION | 16.00 mg | MDE Replacement | ||
| Q2 2024 | SACCHARIN | ORAL | GRANULE, FOR SOLUTION | 16mg | MDE Replacement | ||
| Q1 2024 | SIMETHICONE | ORAL | GRANULE, FOR SUSPENSION | 4.00 mg/ 5.00 ml | MDE Replacement | ||
| Q2 2024 | SIMETHICONE | ORAL | GRANULE, FOR SUSPENSION | 40mg | MDE Replacement | ||
| Q1 2024 | SIMETHICONE EMULSION | ORAL | TABLET, EXTENDED RELEASE | 0.08 mg | MDE Replacement | ||
| Q2 2024 | SIMETHICONE EMULSION | ORAL | TABLET, EXTENDED RELEASE | 2mg | MDE Replacement | ||
| Q1 2024 | SODIUM CHLORIDE | OPHTHALMIC | SUSPENSION/ DROPS | 0.51 %w/v | MDE Replacement | ||
| Q2 2024 | SODIUM CHLORIDE | OPHTHALMIC | SUSPENSION/ DROPS | 3mg | MDE Replacement | ||
| Q1 2024 | SODIUM CHLORIDE | RETROBULBAR | INJECTION | 0.86 %w/v | MDE Replacement | ||
| Q2 2024 | SODIUM CHLORIDE | RETROBULBAR | INJECTION | 648mg | MDE Replacement | ||
| Q1 2024 | SODIUM HYDROXIDE | INTRAMUSCULAR | INJECTION, SOLUTION | 0.13 %w/v | MDE Replacement | ||
| Q2 2024 | SODIUM HYDROXIDE | INTRAMUSCULAR | INJECTION, SOLUTION | 78mg | MDE Replacement | ||
| Q1 2024 | SODIUM HYDROXIDE | INTRAVENOUS | INJECTION, SOLUTION | 2.83 %w/v | MDE Replacement | ||
| Q2 2024 | SODIUM HYDROXIDE | INTRAVENOUS | INJECTION, SOLUTION | 78mg | MDE Replacement | ||
| Q1 2024 | SODIUM HYDROXIDE | OPHTHALMIC | GEL | 1.85 %w/w | MDE Replacement | ||
| Q2 2024 | SODIUM HYDROXIDE | OPHTHALMIC | GEL | 6mg | MDE Replacement | ||
| Q1 2024 | SORBITAN MONOOLEATE | ORAL | CAPSULE | 153.90 mg | MDE Replacement | ||
| Q2 2024 | SORBITAN MONOOLEATE | ORAL | CAPSULE | 200mg | MDE Replacement | ||
| Q1 2024 | SORBITOL SOLUTION | TOPICAL | LOTION | 10.70 %w/w | MDE Replacement | ||
| Q2 2024 | SORBITOL SOLUTION | TOPICAL | LOTION | 764mg | MDE Replacement | ||
| Q1 2024 | STEAROYL POLYOXYLGLYCERIDES | ORAL | CAPSULE | 260.00 mg | MDE Replacement | ||
| Q2 2024 | STEAROYL POLYOXYLGLYCERIDES | ORAL | CAPSULE | 2350mg | MDE Replacement | ||
| Q1 2024 | SUCROSE DISTEARATE | TOPICAL | CREAM | 5.00 %w/w | MDE Replacement | ||
| Q2 2024 | SUCROSE DISTEARATE | TOPICAL | CREAM | 25mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: March 15, 2024
Database Last Updated: April 29, 2024